Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Sanative Patches for Advanced Regenerative Engineering of the Heart

Project description

Advances in cardiac regeneration to heal broken hearts

Heart disease remains the world’s leading killer, and damaged heart muscle cannot heal itself. With this in mind, the ERC-funded SPARE HEART project aims to change that with groundbreaking regenerative therapy. By 3D-printing thick, vascularised cardiac patches from human stem cells, researchers hope to restore damaged heart tissue, not just manage symptoms. These engineered tissues (containing beating cardiomyocytes and blood-vessel-forming cells) will be matured in custom bioreactors to ensure strength and surgical usability. The goal is proof-of-concept surgery in pigs, demonstrating real regenerative potential and pushing the technology toward clinical trials. If successful, SPARE HEART could revolutionise cardiac care, offering a lifeline to millions living with irreversible heart damage.

Objective

Cardiovascular diseases are the leading cause of death in the world. Because the human heart has effectively no regenerative capabilities, the damage caused by cardiovascular diseases and heart attacks is both cumulative and progressive. The aim of this project is the development of regenerative tissue-engineered cardiac patches, which will revolutionize healthcare by providing patients with a treatment that seeks not to manage their symptoms, but to correct and reverse the underlying damage to the cardiac muscle. While the theory underpinning regenerative cardiac patches is not novel, reaching TRL5/6 by demonstrating proof-of-concept with 3D-printed, thick, fully vascularized, clinically relevant patches would constitute an extraordinary step forward for the field.
In this project, we propose to 3D-print thick, vascularized cardiac tissues comprised of functional cardiomyocytes and blood vessel–forming endothelial cells derived from human induced pluripotent stem cells (iPSCs). The tissues will be between ½ -1 cm thick and will require significant levels of vascularization. Following fabrication, tissues will be matured in custom-designed bioreactors and reinforced, rendering them strong enough to be easily handled by surgeons. We then propose to perform cardiac-regenerative surgery in a large mammal model (pigs). This study will serve as a proof-of-concept that will advance the technology from an academic setting to the biotech industry and ultimately into the clinic.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

TEL AVIV UNIVERSITY
Net EU contribution
€ 150 000,00
Total cost
No data

Beneficiaries (1)